Michelle L. Mellion Sells 9,260 Shares of PepGen Inc. (NASDAQ:PEPG) Stock

PepGen Inc. (NASDAQ:PEPG) insider Michelle L. Mellion sold 9,260 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $18.19, for a total value of $168,439.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Michelle L. Mellion also recently made the following trade(s):

• On Tuesday, June 11th, Michelle L. Mellion sold 500 shares of PepGen stock. The stock was sold at an average price of $18.04, for a total value of $9,020.00.

PepGen Trading Down 2.7 %

Shares of PEPG stock opened at $16.46 on Friday. The stock’s fifty day simple moving average is $14.92 and its 200-day simple moving average is $12.39. PepGen Inc. has a 1-year low of $3.72 and a 1-year high of $18.72.

PepGen (NASDAQ:PEPG) last issued its earnings results on Tuesday, May 14th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.11. Equities analysts predict that PepGen Inc. will post -2.87 earnings per share for the current year.

Institutional Investors Weigh In On PepGen

Institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new position in shares of PepGen in the first quarter worth $30,000. Artal Group S.A. acquired a new position in PepGen in the 1st quarter worth about $2,940,000. Adage Capital Partners GP L.L.C. raised its stake in shares of PepGen by 18.3% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 680,000 shares of the company’s stock worth $3,454,000 after purchasing an additional 105,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of PepGen by 68.0% during the 1st quarter. Vanguard Group Inc. now owns 850,445 shares of the company’s stock valued at $12,502,000 after buying an additional 344,266 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of PepGen by 18.1% in the 1st quarter. Janus Henderson Group PLC now owns 1,166,642 shares of the company’s stock valued at $17,225,000 after buying an additional 178,438 shares in the last quarter. Institutional investors and hedge funds own 58.01% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of PepGen in a research note on Wednesday, May 15th. Wedbush restated an “outperform” rating and set a $20.00 price target on shares of PepGen in a report on Wednesday, May 15th.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.